Prospective Analysis of the Use of TEG in Stroke Patients

Sponsor

The University of Texas Health Science Center, Houston (Other)

Overall Status

Completed

CT.gov ID

NCT02494726

Collaborator

(none)

178

Enrollment

Location

Duration (Months)

2.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The overall purpose of this study is to evaluate how effective Thromboelastography (TEG) is on identifying ischemic and hemorrhagic stroke patients at increased risk for bleeding after receiving tissue plasminogen activator (tPA), as well as on differentiating between patients in whom optimal thrombolysis has been achieved, and those whom it has not.

Condition or Disease	Intervention/Treatment	Phase
Ischemic Stroke Brain Hemorrhage	Other: Thromboelastography

Detailed Description

Thromboelastography (TEG), a computerized analysis that has been used since the 1940s, is the only stand alone test that can provide integrated information on the balance between the two separate but simultaneously occuring components of coagulation, thrombosis and lysis. It measures the coagulation process from initial clotting cascade to clot strength.

TEG may be used to assess the coagulation status of patients with acute stroke, whether ischemic or hemorrhagic. TEG might also be a useful way to predict and assess the degree of fibrinolysis that is achieved by tissue plasminogen activator (tPA). Currently tPA is given as a standard dose determined by the patient's body weight, thus given the variability in patient outcome after tPA, this dose could sometimes be too small or too large, leading to thrombolysis or bleeding, respectively. One of the purposes of this observational study is to evaluate how effective TEG is on predicting and assessing the degree of thrombolysis following tPA therapy, by producing a range of TEG values correlated with optimal thrombolysis.

The results of the recent FAST trial demonstrated the need to identify patients with spontaneous intracerebral hemorrhage (ICH) who are at increased risk for hematoma enlargement. Such identified patients, could benefit from a therapeutic advantage of activated factor VII or other hemostatic agents may be more clearly studied. Therefore, another purpose of this study is to evaluate how effective TEG is on predicting further bleeding for patients with spontaneous ICH.

The study will consist of 208 ischemic patients and 80 hemorrhagic patients, whom which are approached from all stroke patients admitted to Memorial Hermann Hospital Emergency Department receiving a confirmatory CT or MRI scan. Patients who agree to participate will have blood drawn the day of hospital arrival, will then be followed for 36 +/- 12 hours after the stroke, and 90 +/- 30 days after the stroke, all during which two more blood samples will be obtained.

Normal controls will be age and sex matched to the investigators' research population. A one-time blood draw will be obtained and information collected will be age, sex and TEG values.

Study Design

Study Type:

Observational

Actual Enrollment :

178 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Prospective Analysis of the Use of Thromboelastography in Stroke Patients

Study Start Date :

Nov 1, 2009

Actual Primary Completion Date :

May 1, 2014

Actual Study Completion Date :

Dec 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Ischemic Stroke Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)	Other: Thromboelastography TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached. Other Names: TEG
Healthy Controls Healthy controls who have had their blood analyzed using thromboelastography (TEG)	Other: Thromboelastography TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached. Other Names: TEG
Hemorrhagic Stroke Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)	Other: Thromboelastography TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached. Other Names: TEG

Arm

Intervention/Treatment

Ischemic Stroke

Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)

Other: Thromboelastography

TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.

Other Names:

TEG

Healthy Controls

Healthy controls who have had their blood analyzed using thromboelastography (TEG)

Other: Thromboelastography

Other Names:

TEG

Hemorrhagic Stroke

Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)

Other: Thromboelastography

Other Names:

TEG

Outcome Measures

Primary Outcome Measures

Baseline TEG in patients with spontaneous ICH vs age matched controls [TEG obtained within 6 hours of last seen normal in patients with spontaneous ICH]
Compare baseline (within 6 hours of last seen normal) TEG in patients with spontaneous ICH to TEG in age-matched controls.

Secondary Outcome Measures

Rapid clinical improvement after tPA (8 or greater point improvement on NIHSS score or total NIHSS 0 or 1) [Change in NIHSS score from baseline (prior to IV tPA within 4.5 hours of last seen normal) to NIHSS 36 +/- 12 hours after last seen normal.]
Correlate baseline (within 4.5 hours of last seen normal and prior to tPA) and 10 minute post tPA TEG values with rapid clinical improvement

Other Outcome Measures

Hematoma enlargement in patients with spontaneous ICH [CT hematoma volume at 36 +/- 12 hours compared to baseline (within 6 hours of last seen normal)]
Correlate baseline TEG values (within 6 hours of last seen normal) with hematoma enlargement
Hemorrhagic transformation after IV tPA [Any bleeding on post tPA imaging 36 hours +/- 12 hrs after stroke onset]
Correlate baseline TEG values (within 4.5 hours of last seen normal) with hemorrhagic transformation or hemorrhage on CT 36 hours after stroke onset
Arterial recanalization after IV tPA [Recanalization (TICI 2b or 3 flow) on imaging within 36 hours post IV tPA compared to pre-treatment]
Correlate baseline TEG values (within 4.5 hours of last seen normal) with recanalization (TICI 2b or 3 flow) on imaging within 36 hours post IV tPA compared to pre-treatment
Hyperdense Middle Cerebral Artery Sign (HDMCA) [HDMCA on baseline CT in patients receiving IV tPA within 4.5 hours of last seen normal]
Correlate baseline TEG values (within 4.5 hours of last seen normal) with HDMCA on baseline CT imaging

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

At least 18 years of age or older.
Symptoms and signs causing measurable neurologic deficit consistent with an acute stroke.
CT or MRI consistent with stroke (ischemic or hemorrhagic) or with clinical evidence suggesting a stroke.
For acute ischemic stroke patients, treatment with tPA and TEG blood draw must be done within 4.5 hours of symptom onset.
For ICH patients, TEG blood draw must be done within 6 hours of symptom onset.

Exclusion Criteria:

Contraindication to CT and MRI (ex. inability to lie flat)
If ICH patient
Hemorrhage secondary to trauma, arteriovenous malformation (AVM) or crush injury
Planned surgical evacuation (hemicraniectomy and ventriculostomy allowed).
Receipt of hemostatic agents (FFP, Cryo, activated factor seven) prior to TEG blood draw.